Cargando…

Nivolumab-induced psoriasis successfully treated with risankizumab-rzaa in a patient with stage III melanoma

Detalles Bibliográficos
Autores principales:	Glinos, George D., Fisher, William Steele, Morr, Claudia S., Seminario-Vidal, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079959/ https://www.ncbi.nlm.nih.gov/pubmed/33948461 http://dx.doi.org/10.1016/j.jdcr.2021.03.029

Ejemplares similares

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
por: Reddy, Vidhatha, et al.
Publicado: (2020)

Palmoplantar Psoriasis Successfully Treated With Risankizumab
por: Alajlan, Abdulmajeed M, et al.
Publicado: (2021)

Risankizumab for psoriasis
Publicado: (2020)

Rapidly and successful improvement of nail psoriasis with risankizumab
por: Orsini, Diego, et al.
Publicado: (2023)

Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022)

A Case of Recalcitrant Circinate Generalized (Lapière) Psoriasis Successfully Treated with Risankizumab
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Risankizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Successful treatment of psoriasis with risankizumab in a patient with telangiectasia macularis eruptiva perstans
por: Barber, Cara, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
por: Pang, Yinuo, et al.
Publicado: (2019)

Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
por: Witjes, Han, et al.
Publicado: (2019)

Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
por: Khatri, Amit, et al.
Publicado: (2019)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
por: Haugh, Isabel M, et al.
Publicado: (2018)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

A case of nail psoriasis improved with treatment by risankizumab
por: AlAjlan, Abdulmajeed, et al.
Publicado: (2022)

Use of risankizumab in two HIV-positive patients with psoriasis
por: Maliyar, Khalad, et al.
Publicado: (2023)

Mycosis fungoides diagnosed after exposure to risankizumab for psoriasis
por: Fahmy, Lauren M., et al.
Publicado: (2023)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report
por: Al Muqrin, Abdullah Muqrin, et al.
Publicado: (2022)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Eruptive lentiginosis in resolving plaque psoriasis during treatment with risankizumab
por: Palmisano, Gerardo, et al.
Publicado: (2023)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: a Report of Two Cases
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Successful treatment of a refractory pyoderma gangrenosum with risankizumab
por: Burgdorf, Birte, et al.
Publicado: (2020)

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children
por: Kołt-Kamińska, Marta, et al.
Publicado: (2023)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Pharmacovigilance of Risankizumab in the Treatment of Psoriasis and Arthritic Psoriasis: Real-World Data from EudraVigilance Database
por: Calapai, Fabrizio, et al.
Publicado: (2023)

Risankizumab for Plaque and Guttate Psoriasis in a Patient with IgA-Related Glomerulonephritis
por: Dattola, Annunziata, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis
por: Barber, Cara, et al.
Publicado: (2022)

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
por: Suleiman, Ahmed A., et al.
Publicado: (2019)

Refractory Sweet's syndrome successfully treated with rituximab
por: Seminario-Vidal, Lucia, et al.
Publicado: (2015)

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic
por: Gkalpakiotis, Spyridon, et al.
Publicado: (2021)

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment
por: Yu, Qianying, et al.
Publicado: (2022)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
por: Gracia-Cazaña, Tamara, et al.
Publicado: (2023)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
por: Mandalá, Mario, et al.
Publicado: (2021)

Nivolumab-induced lichen planus responsive to dupilumab treatment in a patient with stage III C melanoma
por: Zemlok, Sarah Kamsiah, et al.
Publicado: (2023)

Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report
por: Ito, Shingo, et al.
Publicado: (2021)

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
por: Crowley, Jeffrey J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2441va15frro0bjqk2h73pj6a6